Mounjaro, the weight loss injection developed by pharmaceutical firm Lilly, is set to be prescribed on the NHS for the first ...

Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

GPs in England will be able to prescribe weight loss jabs for the first time on the NHS on Monday, as the health service ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...